Get informed when a big investor buys or sells
+ Follow14.38%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
Regeneron Pharmaceuticals (0R2M.L) currently reports a ROE of 14.38%. That is above the Healthcare sector average of 9.17%. Use the charts on this page to explore Regeneron Pharmaceuticals's ROE history and peer comparisons.
Regeneron Pharmaceuticals's ROE of 14.38% is higher than the Healthcare sector average of 9.17%. That is roughly 56.8% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
There is no universal 'good' ROE, but Regeneron Pharmaceuticals's current 14.38% should be judged against Healthcare norms (sector average: 9.17%) and against 0R2M.L's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.
Start with the current ROE of 14.38%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 9.17%. From there, open related valuation or income-statement pages for Regeneron Pharmaceuticals, and consider following 0R2M.L for alerts when major investors trade the stock.
Regeneron Pharmaceuticals is classified in the Healthcare sector. On ROE, it currently shows 14.38% versus a sector average near 9.17%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing 0R2M.L with unrelated industries.